These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38371197)

  • 1. Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
    Miyake M; Kitamura H; Nishimura N; Miyamoto T; Nakahama T; Fujii T; Matsumoto H; Matsuyama H; Yonemori M; Enokida H; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Nishiyama H; Fujimoto K;
    BJUI Compass; 2024 Mar; 5(2):269-280. PubMed ID: 38371197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
    Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
    Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
    Jobczyk M; Stawiski K; Fendler W; Różański W
    Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
    Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
    Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
    Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
    Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.
    Contieri R; Hensley PJ; Tan WS; Grajales V; Bree K; Nogueras-Gonzalez GM; Lee BH; Navai N; Dinney CP; Kamat AM
    Eur Urol Oncol; 2023 Dec; 6(6):590-596. PubMed ID: 37558542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
    Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
    Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.
    Lammers RJ; Palou J; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
    BJU Int; 2014 Aug; 114(2):193-201. PubMed ID: 24304638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center.
    Scilipoti P; Longoni M; de Angelis M; Re C; Bertini A; Cannoletta D; Burgio G; Lucianò R; Rosiello G; Colombo R; Gandaglia G; Salonia A; Montorsi F; Briganti A; Moschini M
    Urol Oncol; 2024 Dec; 42(12):451.e1-451.e10. PubMed ID: 39060208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
    Eur Urol; 2011 Jun; 59(6):997-1008. PubMed ID: 21458150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EAU guidelines on non-muscle-carcinoma of the bladder].
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J;
    Actas Urol Esp; 2009 Apr; 33(4):361-71. PubMed ID: 19579886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis.
    Nishikawa R; Miyake M; Morizane S; Shimizu R; Teraoka S; Honda M; Iida K; Nishimura N; Sazuka T; Kimura T; Ito A; Shiga K; Taoka R; Kojima T; Kobayashi T; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Takenaka A
    Int J Urol; 2023 Mar; 30(3):299-307. PubMed ID: 36448522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J;
    Eur Urol; 2008 Aug; 54(2):303-14. PubMed ID: 18468779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Sylvester RJ; Rodríguez O; Hernández V; Turturica D; Bauerová L; Bruins HM; Bründl J; van der Kwast TH; Brisuda A; Rubio-Briones J; Seles M; Hentschel AE; Kusuma VRM; Huebner N; Cotte J; Mertens LS; Volanis D; Cussenot O; Subiela Henríquez JD; de la Peña E; Pisano F; Pešl M; van der Heijden AG; Herdegen S; Zlotta AR; Hacek J; Calatrava A; Mannweiler S; Bosschieter J; Ashabere D; Haitel A; Côté JF; El Sheikh S; Lunelli L; Algaba F; Alemany I; Soria F; Runneboom W; Breyer J; Nieuwenhuijzen JA; Llorente C; Molinaro L; Hulsbergen-van de Kaa CA; Evert M; Kiemeney LALM; N'Dow J; Plass K; Čapoun O; Soukup V; Dominguez-Escrig JL; Cohen D; Palou J; Gontero P; Burger M; Zigeuner R; Mostafid AH; Shariat SF; Rouprêt M; Compérat EM; Babjuk M; van Rhijn BWG
    Eur Urol; 2021 Apr; 79(4):480-488. PubMed ID: 33419683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.